Evidence map›Paper›PMID 36273142›Full record

ArticleBMC nephrology2022

Predictors of shorter- and longer-term mortality after COVID-19 presentation among dialysis patients: parallel use of machine learning models in Latin and North American countries.

Adrián M Guinsburg, Yue Jiao, María Inés Díaz Bessone, Caitlin K Monaghan, Beatriz Magalhães, Michael A Kraus, Peter Kotanko, Jeffrey L Hymes, Robert J Kossmann, Juan Carlos Berbessi and 3 more

Open access · goldAbstract read
In one paragraph

Article in BMC nephrology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Adrián M GuinsburgFresenius Medical Care Latin America, Rio de Janeiro, Brazil.
Yue JiaoFresenius Medical Care, Global Medical Office, 920 Winter Street, Waltham, MA, 02451, USA.
María Inés Díaz BessoneFresenius Medical Care Latin America, Rio de Janeiro, Brazil.
Caitlin K MonaghanFresenius Medical Care, Global Medical Office, 920 Winter Street, Waltham, MA, 02451, USA.
Beatriz MagalhãesFresenius Medical Care Latin America, Rio de Janeiro, Brazil.
Michael A KrausFresenius Medical Care North America, Waltham, USA.
Peter KotankoRenal Research Institute, New York, USA.
Jeffrey L HymesFresenius Medical Care, Global Medical Office, 920 Winter Street, Waltham, MA, 02451, USA.
Robert J KossmannFresenius Medical Care North America, Waltham, USA.
Juan Carlos BerbessiFresenius Medical Care Latin America, Rio de Janeiro, Brazil.
Franklin W MadduxFresenius Medical Care AG & Co. KGaA, Global Medical Office, Bad Homburg, Germany.
Len A UsvyatFresenius Medical Care, Global Medical Office, 920 Winter Street, Waltham, MA, 02451, USA.
John W LarkinFresenius Medical Care, Global Medical Office, 920 Winter Street, Waltham, MA, 02451, USA. John.Larkin@freseniusmedicalcare.com.
Fresenius Medical Care North America (United States)Fresenius Medical Care (United States) · USFresenius Medical Care (Germany) · DERenal Research Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe developed machine learning models to understand the predictors of shorter-, intermediate-, and longer-term mortality among hemodialysis (HD) patients affected by COVID-19 in four countries in the Americas.

methodsWe used data from adult HD patients treated at regional institutions of a global provider in Latin America (LatAm) and North America who contracted COVID-19 in 2020 before SARS-CoV-2 vaccines were available. Using 93 commonly captured variables, we developed machine learning models that predicted the likelihood of death overall, as well as during 0-14, 15-30, > 30 days after COVID-19 presentation and identified the importance of predictors. XGBoost models were built in parallel using the same programming with a 60%:20%:20% random split for training, validation, & testing data for the datasets from LatAm (Argentina, Columbia, Ecuador) and North America (United States) countries.

resultsAmong HD patients with COVID-19, 28.8% (1,001/3,473) died in LatAm and 20.5% (4,426/21,624) died in North America. Mortality occurred earlier in LatAm versus North America; 15.0% and 7.3% of patients died within 0-14 days, 7.9% and 4.6% of patients died within 15-30 days, and 5.9% and 8.6% of patients died > 30 days after COVID-19 presentation, respectively. Area under curve ranged from 0.73 to 0.83 across prediction models in both regions. Top predictors of death after COVID-19 consistently included older age, longer vintage, markers of poor nutrition and more inflammation in both regions at all timepoints. Unique patient attributes (higher BMI, male sex) were top predictors of mortality during 0-14 and 15-30 days after COVID-19, yet not mortality > 30 days after presentation.

conclusionsFindings showed distinct profiles of mortality in COVID-19 in LatAm and North America throughout 2020. Mortality rate was higher within 0-14 and 15-30 days after COVID-19 in LatAm, while mortality rate was higher in North America > 30 days after presentation. Nonetheless, a remarkable proportion of HD patients died > 30 days after COVID-19 presentation in both regions. We were able to develop a series of suitable prognostic prediction models and establish the top predictors of death in COVID-19 during shorter-, intermediate-, and longer-term follow up periods.

Indexed as

COVID-19AdultCOVID-19 VaccinesFemaleHumansMachine LearningMaleNorth AmericaRenal DialysisSARS-CoV-2COVID-19 VaccinesCOVID-19HemodialysisMachine LearningMortality RiskMultinationalPrediction Model

Identifiers

PMID36273142
PMCPMC9587666
OpenAlexW4307136024

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.